Home > News > Content
NeuroActin An Extract Of Andrographis Paniculata From American HP Ingredients Company, Won A Patent From The European Union.
Feb 11, 2019

Recently, NeuroActin, an extract of Andrographis paniculata from American HP ingredients company, won a patent from the European Union.

Recent animal studies have shown that Andrographis paniculata extract has potential health benefits for Alzheimer's disease.

It is reported that the name of the patent approved by the European Union is Andrographolide for Alzheimer's treatment and cognitive rehabilitation, which is also the health claim of Andrographolide. Andrographolide is extracted from the stems and leaves of Andrographis paniculata, which claims to be "a method for the treatment of human Alzheimer's disease dementia, in which the effective dose of Andrographolide is 1-4 mg/kg orally".

HP's application includes clinical data from the company, which found that andrographolide prevented or even reversed neuropathy in mice with Alzheimer's disease. 

It was found that andrographolide could help restore the spatial memory function of mice, reduce the content of amyloid beta-peptide (Abet) in the brain of mice, and increase the excitatory postsynaptic potential. In the patent application, the researchers believe that the results show that andrographolide can be used as a potential preventive and reversible treatment in the progression of Alzheimer's disease.

HP's Andrographis paniculata extract has received support from the FDA and the EU, suggesting that more technological research has contributed to the formulation of specific claims. Although the FDA has strict control over NeuroActin, EU patent acquisition is encouraging. He supports NeuroActin as a supplement to support healthy brain structure and function and improve cognitive acuity and memory.